Bateman Lab

Bateman’s laboratory focuses on the causes, diagnosis and future treatments of Alzheimer’s disease (AD). We directly measure the pathology and pathophysiology of AD in humans using multiple techniques. Our group uses a wide variety of assays and techniques from the most basic applications, such as quantitative measurement of stable-isotope labeled peptides, to clinical translational studies in diagnostic and therapeutic biomarkers for AD.

Randall J. Bateman, MD

Principal Investigator

Randall J. Bateman, MD, is the Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine, director of the Dominantly Inherited Alzheimer Network (DIAN) and director of the DIAN Trials Unit (DIAN-TU).

Bateman’s laboratory investigates the causes and methods of diagnosis and treatment of Alzheimer’s disease (AD) utilizing a wide variety of assays and techniques from…

Read more

SILQ, Washington University School of Medicine

New center’s aim: to ID biomarkers of neurodegenerative diseases (Links to an external site)

July 21, 2022

A new center established at Washington University School of Medicine in St. Louis aims to accelerate research into biomarkers of neurodegenerative conditions such as Huntington’s and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and the so-called tauopathies, a group that includes Alzheimer’s disease along with rarer diseases such as frontotemporal dementia, corticobasal syndrome […]

SILQ, Washington University School of Medicine

Blood test for Alzheimer’s highly accurate in large, international study (Links to an external site)

February 22, 2022

“A blood test for Alzheimer’s provides a huge boost for Alzheimer’s research and diagnosis, drastically cutting the time and cost of identifying patients for clinical trials and spurring the development of new treatment options,” Bateman said. “As new drugs become available, a blood test could determine who might benefit from treatment, including those at very early stages of the disease.”